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KESAN PROGRAM INTERVENSI KOMBINASI TINGKAH LAKU, 
PENDIDIKAN PEMAKANAN DAN AKTIVITI FIZIKAL (COMBINE) KE 
ATAS PENANDA HEMOSTATIK DALAM SUBJEK OBES  
  
ABSTRAK 
 
Obesiti merupakan keadaan pengumpulan lemak berlebihan yang menimbun di 
dalam badan seseorang, dan ia meningkatkan risiko penyakit jantung koronari. 
Kajian ini adalah bertujuan untuk mendapatkan data saintifik mengenai kesan 
program intervensi kombinasi tingkah laku, pendidikan pemakanan dan aktiviti 
fizikal (COMBINE) ke atas data antropometri, ujian darah biokimia dan penanda 
hemostatik. Kajian penurunan berat badan ini mengambil masa selama 12 minggu  
yang telah melibatkan 28 subjek obes. Semua subjek dikehendaki menandatangani 
borang keizinan menyertai program terlebih dahulu sebelum menyertai program. 
Data antropometri diukur ke atas semua subjek sebelum intervensi dan selepas 
intervensi. Sebanyak 15 ml darah diambil 2 kali iaitu sebelum intervensi dan selepas 
tamat program. Ujian-ujian penanda hemostatik adalah seperti tahap fibrinogen, 
factor VII, thrombin activatable fibrinolytic inhibitors (TAFI), tissue plasminogen 
activators (t-PA), plasminogen activator inhibitors-1(PAI-1), plasminogen dan 
Heparin Cofactor II. Manakala ujian biokimia termasuk ujian glukosa dan ujian lipid.  
Pakej penurunan berat badan ini termasuk berjalan kaki, senaman ‘dumb bell’, 
senamrobik dan diikuti pendidikan pemakanan yang dijalankan di Hospital Universiti 
Sains Malaysia pada setiap hari Khamis bermula jam 8 pagi hingga 1.00 tengahari. 
Semua data dianalisis menggunakan ujian ´paired t-test’, SPSS 18.0. Manakala 
´Spearman`s rho’digunakan untuk mengetahui hubungkait diantara penanda 
 xvi 
hemostatik dengan lain-lain parameter. Paras p<0.05 dianggap signifikan bagi semua 
analisis. Bagi indek jisim tubuh (BMI), terdapat penurunan yang signifikan iaitu 
(33.22 ± 0.67 kg/m²)  selepas intervensi berbanding  (35.78 ± 0.82 kg/m²) sebelum 
intervensi. Begitu juga terdapat keputusan yang signifikan untuk lain-lain data 
antropometri seperti ukuran lilitan pinggang dan komposisi badan. Bagi ujian 
penanda hemostasis, terdapat perbezaan penurunan yang signifikan selepas tamat 
program ke atas lima penanda hemostasis iaitu ujian ke atas fibrinogen, factor VII, t-
PA, PAI-1 dan TAFI, begitu juga dengan paras trigliserida, mengalami penurunan 
sebelum intervensi (1.73 ± 0.18 mmol/L) kepada 1.24 ± 0.07 mmol/L selepas 
intervensi, (p<0.05). Sementara itu, kenaikan signifikan didapati pada paras Heparin 
Cofactor II selepas tamat intervensi (119.89 ± 3.58%), berbanding sebelum 
intervensi (105.22 ± 4.42%) (p<0.05). Tetapi, tiada perubahan signifikan pada paras 
plasminogen, kolesterol, lemak tepu tinggi, lemak tepu rendah dan paras glukosa. 
Secara kesimpulannya, pendekatan intervensi tanpa melibatkan farmakologi ini boleh 
dianggap sabagai satu kejayaan berpandukan keputusan positif didapati dalam 
penurunan bahaya penanda hemostatik dan juga penurunan fizikal parameter serta 
ujian biokimia. Semua ujian ini perlu diuji dengan lebih mendalam lagi untuk 
dijadikan sebagai panduan keberkesanan dalam program penurunan berat badan pada 
masa akan datang. 
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THE EFFECTS OF COMBINATION OF BEHAVIOURAL INTERVENTION, 
NUTRITIONAL EDUCATION AND EXERCISE (COMBINE) PROGRAM 
ON HAEMOSTATIC MARKERS AMONG OBESE SUBJECTS 
 
ABSTRACT 
 
Obesity is a condition of excess body fat and it significantly increases the risk of 
coronary heart disease. Studies have shown that impaired haemostatic in obesity 
were found to predict future development of coronary heart disease and numbers of 
coronary events. The purpose of this study was to determine the effects of 
COMBINE program on the changes of anthropometry parameters, biochemical 
profile and haemostatic markers in obese subjects. The assessment was carried out on 
28 obese subjects for 12-week duration.  All subjects were required to give an 
informed consent before enrolling into the study. Anthropometric data were 
measured from the subjects selected before intervention (baseline) and after 
completing the program (post-intervention). About 15 ml of blood specimen was 
drawn from all subjects and tested for biochemical profile (e.g. fasting blood glucose 
and lipid profile) and haemostatic markers, such as fibrinogen, factor VII, thrombin 
activatable fibrinolytic inhibitors (TAFI), tissue plasminogen activators (t-PA), 
plasminogen activator inhibitors-1(PAI-1), plasminogen and Heparin Cofactor II at 
baseline and at post intervention. During this intervention period, the subjects were 
involved in a weekly program from 8.00 am until 1.00 pm on every Thursday at 
Hospital Universiti Sains Malaysia. The package of weight loss program consisted of 
brisk walking, dumb bell and easy-style of aerobic dance accompanied with nutrition 
education modules. Their food intake and physical activity were recorded in diary 
and they act as important tools in the behaviour modification method. Data analysis 
 xviii 
for this study was carried out using paired t-test, SPSS 18.0. In order to correlate the 
haemostatic markers with other parameters, Spearman`s rho correlation analysis was 
used. The significant level, p< 0.05 was used.  The results showed that there was a 
significant reduction in the BMI at post intervention (33.22 ± 0.67 kg/m²) when 
compared to pre intervention (35.78 ± 0.82 kg/m²). Similarly, there was a significant 
reduction (p<0.05) for other anthropometric data such as waist circumference and 
body composition analysis. Besides that there was also significant reduction in five 
haemostatic markers such as fibrinogen, factor VII, TAFI, t-PA and PAI-1 at post-
intervention when compared to baseline. Similarly, there was a significant reduction 
in triglyceride level at the baseline (1.73 ± 0.18 mmol/L) compared to post-
intervention, (1.24 ± 0.07mmol/L) (p< 0.05). Meanwhile there was a significant 
increased level of Heparin Cofactor II after the intervention (119.89 ± 3.58%) 
compared to baseline (105.22 ± 4.42%) (p< 0.05). But, there was no significant 
difference seen in plasminogen level as well as in cholesterol, high density 
lipoprotein, low density lipoprotein and fasting blood glucose levels. In conclusion, 
the non-pharmacologic approach as an intervention is considered a successful 
program based on the positive findings such as reduced haemostatic hazard markers 
and improved other parameters such as physical parameters and biochemical 
markers. These markers should be further explored to be utilised as predictors to 
determine the effectiveness of a weight loss program and to predict the risk to 
develop cardiovascular disease in obese subjects. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
 
Obesity is one of the most serious public health problems and is a leading preventable 
cause of death worldwide (Barnes et al., 2007). Obesity contributes to a shorter 
expectation of life, increased morbidity, or cost to the community in terms of both 
money and anxiety (Waterlow, 1976). 
 
Obesity is a condition of excess body fat and in most cases results from energy intake in 
their diet over a period of time, has exceeded their energy expenditure for metabolism, 
physical activity and growth. Obesity continues to be a prevalent public health problem 
in the developed countries, while there is strong epidemiological evidence indicating 
that the prevalence of obesity in developing countries often increases in communities 
emerging from lifestyles of subsistence into affluence (Ismail et al., 2005). 
 
Various studies have suggested that obesity per se is an independent cardiovascular risk 
factor, as well as predisposing to type 2 diabetes, hypertension, and dyslipidaemia 
(Gallist et al., 2000; Masahiko et al., 2004; Kristine et al., 2005). Obese subjects are at 
risk for the development of cardiovascular disease, which can in part be explained by 
disturbances in the haemostatics and fibrinolytic system. Indeed, obese subjects tend to 
 2 
have higher values of fibrinogen, factor VII, factor VIII and plasminogen activator 
inhibitor -1 (PAI-1) compared to non-obese subjects (Mertens et al., 2002).  
 
There are many health benefits and financial gains that can be achieved by reducing 
obesity. It is an essential need for all health care providers to work towards a common 
goal and to take an active role in addressing obesity. The National Heart, Lung, and 
Blood Institute of the National Institutes of Health (2007), recommends lifestyle 
modification as the primary intervention. 
 
 In relation to the obesity issues discussed above, a combination of behavioral 
intervention, nutritional education and exercise (COMBINE) program was introduced in 
USM in 1990. This is a safe method of weight reduction practice recommended to obese 
subjects attending the Obesity Clinic at Hospital Universiti Sains Malaysia. 
 
1.2 Obesity overview 
 
1.2.1 Definition of Obesity  
 
Obesity is a condition of abnormal or excessive fat accumulation in adipose tissue, 
which is associated with a variety of health problems. However, obese individuals may 
differ with the degree of excess fat, and regional distribution of the fat within the body. 
Indeed, excess abdominal fat is a great risk factor for cardiovascular disease compared 
to excess body fat per se (WHO 1998). 
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1.2.2 Body Mass Index (BMI)  
 
Body Mass Index is defined as body weight in kg divided in meter squared as shown 
below. 
                                BMI = Weight (kg)/Height (m²) 
 
This indicator is commonly utilized in epidemiological studies, to predict obesity-related 
morbidity and mortality in adults. A BMI of 30 kg/m2
 
 is considered the threshold of 
obesity. BMI however, does not distinguish between weight associated with muscle and 
weight associated with fat. BMI is considered to provide the most useful, albeit crude, 
population-level measure of obesity. The classification of weight status in adults as 
proposed by WHO (1998) is shown in Table 1.1  
The current classification has been questioned because of possible population difference 
in the risk of co-morbidities and attempts have been made to redefine the classification 
of obesity using BMI for Asian (World Health Organization, International Association 
for the Study of Obesity, International Obesity Task Force, 2000 (WHO/IASO/IOTF)) 
population based on studies by Ko et al., (1999) and Deurenberg-Yap et al., (2000).  
 
However the WHO Expert Consultation Committee 2004 has recommended to retain the 
current WHO classification of BMI (WHO 1998) and acknowledged the need to have 
public health action as recommended (Table 1.2). 
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Table 1.1: Classification of weight status in adults according to Body Mass Index (BMI)  
 
Classification BMI (kg/m2 Risk of co-morbidities ) 
Underweight  
 
< 18.5  
 
Low (but risk of other clinical problems 
increased)  
Normal range  
 
18.5 – 24.9  
 
Average  
Overweight:  
 
≥ 25  
 
    - 
Pre-obese 25 – 29.9  
 
Increased  
 
Obese class I  
 
30.0 – 34.9  
 
Moderate  
 
Obese class II  
 
35.0 – 39.9  
 
Severe  
 
Obese class III  
 
≥40.0  
 
Very severe  
 
 
 Source: World Health Organization (WHO), 1998. 
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Table 1.2: Classification of weight status according to BMI in Asian Adults  
 
Classification BMI (kg/m2) Risk of co-morbidities 
Underweight 
 
< 18.5  
 
Low (but risk of other 
clinical problems increased)  
 
Normal range  
 
18.5 – 22.9  
 
Average  
 
Overweight:  
 
> 23.0  
 
    - 
At Risk  
 
23.0 – 24.9  Increased 
 
Obese class I  
 
25.0 – 29.9 Moderate  
 
Obese class II  
 
> 30.0  
 
Severe  
 
 
Source: World Health Organization, International Association for the Study of Obesity, 
International Obesity Task Force (WHO/IASO/IOTF) 2000. 
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1.2.3 Waist Circumference 
 
Regarding the health risks related to obesity, we have to take into account not only the 
magnitude of obesity but also, and perhaps more relevant, the body fat distribution. 
There are two main types of obesity regarding the fat distribution pattern: android or 
central type obesity with the majority of fat depots located in the abdominal area, both 
subcutaneous and visceral, and gynoid or peripheral obesity in which the fat depots are 
mainly located subcutaneously in the lower body (hips and lower extremities). The 
difference between both types is fundamental, because the metabolic and cardiovascular 
complications of obesity are almost exclusively related to visceral fat depots. 
 
The BMI does not provide any indication of the distribution of fat in the body. Waist 
circumference is positively correlated with abdominal fat. Hence, waist circumference is 
a valuable additional alternative method in identifying individuals at increased risk. 
Waist circumference (WC) is a convenient and simple measurement which is unrelated 
to height and correlates closely with BMI and Waist-Hip Ratio.  It is an approximate 
index of intra-abdominal fat mass. Thus, based on current evidence, the following waist 
circumference is associated with an increased risk of co morbidities: 
• Men ≥ 90cm 
• Women ≥ 80cm 
(WHO 1998). 
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1.2.4 Waist-Hip Ratio   
 
Waist Hip Ratio (WHR) is another simple measurement that has been used in 
epidemiological studies in the past but does not provide additional information 
compared to WC. The values that are associated with an increase abdominal fat and 
increased risk of hypertension, diabetes and ischaemic heart disease are: 
• WHR > 0.90 for men  
• WHR > 0.85 for women  
However, waist circumference is the preferred measure of abdominal obesity compared 
to the WHR (WHO 1998). 
 
1.2.5 Body Composition  
 
Body composition is used to describe the percentages of fat, bone and muscle in human 
bodies. Because muscular tissue takes up less space in body than fat tissue, the body 
composition, as well as weight, determines leanness. The National Institute of 
Health (2011) 
 
recommends that a healthy adult male's body should have between 6 to 24 
percent fat and a female should have between 14 to 31 percent fat. Levels higher than 
the recommended value may indicate excess body fat.   
Body composition can be measured in several ways. The common method is by using a 
set of measurement calipers to measure the thickness of subcutaneous fat in multiple 
places on the body. Another common method is bioelectrical impedance analysis (BIA), 
which uses the resistance of electrical flow through the body to estimate body fat. 
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Besides that, others reference methods are available to estimate body composition 
accurately at the individual level. Multicompartment models, underwater weighing, air 
displacement plethysmography, labeled water techniques and dual-energy X-ray 
absorptiometry (DXA) are the most reliable methods to obtain accurate measures of total 
body fat (Parker et al., 2003).  Computed tomography and magnetic resonance imaging 
have been shown to provide information about body fat distribution (Brambilla et al., 
1994).   However, these reference methods are still not suitable for use because they are 
costly. Therefore, anthropometry and bioelectrical impedance are more widely used 
especially when the size of the population is large and they are also cheaper.  
 
The bioelectrical impedance analysis (BIA) is a method for estimating body composition, 
meaning it measures how much of body weight is fat and how much is nonfat. The 
general principle behind BIA: two conductors are attached to a person's body and a 
small electric current is sent through the body. The resistance between the conductors 
will provide a measure of body fat, since the resistance to electricity varies 
between adipose, muscular and skeletal tissue. Fat-free mass (FFM) is a good conductor 
as it contains a large amount of water (approximately 73%) and electrolytes, while fat is 
anhydrous and a poor conductor of electric current. FFM is composed of all non-fat 
tissues and represents the main active component from the metabolic point of view. A 
main function of fat mass is as an energy reserve, because it consists of triglycerides, 
which has a high caloric power (Claude et al., 2000). Factors that affect the accuracy and 
precision of this method include instrumentation, subject factors, technician skill, and 
the prediction equation formulated to estimate the FFM. Another variable that can affect 
the amount of body fat measured by this method is the amount of liquid an individual 
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has consumed before the test. As electricity travels more easily through water, if a 
person has consumed a large amount of water before the test, the results will show a 
lower percentage of body fat consumption. Less water will increase the apparent 
percentage of body fat (Parker et al., 2003).  
 
  
1.3   Prevalence of obesity 
 
The global burden of overweight (BMI 25.0 – 29.9) and obesity (BMI ≥ 30.0) is 
estimated at more than 1.1 billion (Ismail et al 2005). The prevalence of obesity is 
rapidly increasing in the United States (U.S.) from 14% in 1971 (Flegal et al., 2002) to 
30.6 % in 2002 (Hedley et al., 2004). 
 
Obesity has been reported to be more common in minority populations, such as African-
Americans and Hispanics, than Caucasians (Cossrow and Falkner 2004). For example, a 
study found that 39% of African-Americans, 33% of Hispanics, and 29% of Caucasians 
meet the criteria of obesity (Hedley et al., 2004).   
 
In the Asia Pacific region, the prevalence of obesity in men is between less than 1% in 
China to about 58% in urban Samoa. In women, obesity prevalence is between less than 
2% in China to about 77% in urban Samoa (WHO/IASO/IOTF, 2000). Local data on 
prevalence of obesity reveals that the problem faced in Malaysia is more serious than 
those reported in other Asian countries (Figure 1.1).  
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Figure 1.1: Prevalence of obesity in Asia Pacific region. (Source: WHO/IASO/IOTF, 
2000). 
 
In Malaysia, the National Health Morbidity Survey (1996) reported that in adult males, 
15.1% were overweight and 2.9% obese; while in adult females, 17.9% were overweight 
and 5.7% obese. It was also reported that the prevalence of obesity is almost similar 
between rural and urban populations. In a nationwide study of 4,600 rural villagers 
throughout Peninsular Malaysia, (Khor et al.,1999) reported a prevalence of 19.8% 
overweight among men and 28.0% among women. The prevalence of obesity was 4.2% 
amongst men and 11.1% among women in the rural community studied. Obesity was 
more common in Malays and Indian compared to Chinese (Lim et al., 2000).  
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Overweight and obesity are also a concern among the older populations in this country. 
In a study among 945 elderly people, mostly Malays, from major functional groups in 
Peninsular Malaysia (Zaitun et al., 1999), the prevalence of overweight was 18.2% and 
obesity was 4.3%.  In another study by Suzana et al., (2003) among 820 elderly Malays 
from four rural areas of  Peninsular Malaysia, the prevalence of overweight and obesity 
were 24.7% and 11.4%, respectively. But the prevalence of obesity amongst those aged 
≥ 18 years old has markedly increased by 280% since the last National Health and 
Morbidity Survey in 1996 (Lekhraj et al., 2007).  
 
1.4 Cardiovascular impact in obesity 
 
The effects of increased body fatness on cardiovascular function are predictable. The 
event affecting the cardiovascular system is initiated by an increase in body weight. A 
higher lean tissue mass as well as increase in oxidative demands of metabolically active 
adipose tissue leads to increase in body oxygen consumption and this is accompanied by 
an absolute increase in cardiac output. However the values are within the normal range 
when they are normalized to body surface area (Peter G Kopelmen, 2002). 
Obesity produces an increment in total blood volume and cardiac output which is partly 
due to increased metabolic demand induced by excess body weight (Alpert MA, 2001). 
Thus, at any given level of activity, the cardiac workload is greater for obese subjects 
compared to lean individuals (Poirier et al., 2001).
The increased demand for cardiac output is achieved by an increase in stroke volume 
while the heart rate remains comparatively unchanged. The obesity-related increase in 
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stroke volume results from an increase in diastolic filling of the left ventricle. The 
volume expansion and increase in cardiac output lead to structural changes of the heart. 
The process results in re-modeling of the left ventricle with eccentric hypertrophy 
(Messerli et al., 1986). If there is a concomitant increase in systemic blood pressure, the 
process is followed by concentric hypertrophy, a typical form of hypertensive heart 
disease (Figure1.2).  
Left atrial enlargement may also occur in normotensive obese individuals but typically in 
the setting of increased left ventricular mass. Left atrial enlargement may not be 
mediated solely through left ventricular diastolic dysfunction impairment but may simply 
reflect a physiological adaptation to the expanded blood volume (Sasson et al., 1996). As 
a consequence, left atrial dilation may mediate the excess risk of atrial fibrillation 
associated with obesity (Backman et al., 1979).  However, left ventricular hypertrophy in 
long-standing obesity and/or the effects of concomitant hypertension may also be 
contributing factors to left atrial enlargement.
 
  
 
 
 
 
 
 13 
 
 
 
 
 
 
 
 
 
Figure 1.2: Summary of events affecting the cardiovascular system.  
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blood volume 
 
    
Increase in lean and fat 
mass, surface area- 
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Increased pre load= Left ventricle 
dilatation 
Increased after load= Left 
ventricle eccentric hypertrophy 
          
Increased stroke volume and 
cardiac output 
Increased in systemic vascular resistance 
Increased in BP= Left ventricle concentric hypertrophy 
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Studies such as Framingham Heart Study, the Manitoba Study, and the Harvard School 
of Public Health Nurses Study, have documented that obesity is an independent 
predictor of clinical coronary heart disease (CHD) (Rabkin et al., 1977, Hubert et al., 
1983 and Manson et al., 1990). The conclusion made by these studies result from 
following up each obese subject for more than two decades. 
CHD is narrowing of the blood vessels that supply blood and oxygen to the heart; it is 
usually due to atherosclerosis (Mosca et al., 2007). Atherosclerosis is a condition in 
which an artery wall thickens as a result of the accumulation of fatty materials such as 
cholesterol. It is a syndrome affecting arterial blood vessels, a chronic inflammatory 
response in the walls of arteries, caused largely by the accumulation of macrophage 
white blood cells and promoted by low-density lipoproteins (plasma proteins that carry 
cholesterol and triglycerides) without adequate removal of fats and cholesterol from the 
macrophages by functional high density lipoproteins (HDL). It is commonly referred to 
as a hardening of the arteries. It is caused by the formation of multiple atheroma (Maton 
et al., 1993). In the context of heart or artery matters, atheroma is commonly referred to 
as atheromatous plaques. Atherogenesis is the developmental process of atheromatous 
plaques. It is characterized by a remodeling of arteries leading to subendothelial 
accumulation of fatty substances called plaques. The build up of an atheromatous plaque 
is a slow process, developed over a period of several years through a complex series of 
cellular events occurring within the arterial wall, and in response to a variety of local 
vascular circulating factors (Maton et al., 1993). 
The blood coagulation system has been alleged to determine the onset and outcome of 
atherosclerosis (Cooper et al., 2000). There are two principal reasons for this 
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presumption. The first reason is that cleavage products from the coagulation system, e.g. 
thrombin, FXa and FVIIa may exert pro and anti-inflammatory effects on endothelial 
cells and leucocytes (Esmon, 2000). Endothelial injury starts the process of 
atherogenesis by the effects of platelets deposition. The ultimate result is narrowing of 
the blood vessels. The second reason is that formation of small blood clots that occlude 
major arteries (in the pre-existing narrowed vessels), has been documented in 
myocardial infarction or ischaemic stroke. This  represents the leading complication of 
atherosclerosis (Fuster et al., 1996). 
Platelets  are involved in the initiation of early atherosclerotic lesions, together with 
other factors they contribute to the progression of plaque growth and may lead to 
deleterious clinical events if a pro-thrombotic state is present at the time of plaque 
fissuring or rupture (Fuster et al., 1992). 
 
There are two main types of measurements related to haemostatic disturbances in the 
investigation of the pro-thrombotic state in cardiovascular disease: measurement of 
haemostatic factors levels and measurement of activation products of haemostasis. In the 
former type of measurements, the most promising factors identified have been 
fibrinogen, factor VII (FVII) and the fibrinolytic variables i.e tissue-type plasminogen 
activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) (Fareed et al., 1998). 
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1.5 Overview of Haemostasis 
 
Haemostasis is derived from the Greek meaning “The stoppage of blood flow”. The 
haemostatic system is a vital protective mechanism that refers to the process for 
preventing blood loss by sealing sites of injury in the vascular system. The components 
of normal haemostasis are: the blood vessels, platelets, blood coagulation factors, 
inhibitors of coagulation, and the fibrinolytic system. However, this system must also be 
controlled so that the blood loss does not coagulate within the vasculature and restrict 
the normal blood flow. In other words, the integrity and patency of the haemostatic 
systems depends upon balance between coagulation activation, inhibition and 
fibrinolytic activity. Haemostasis is determined by the interaction of endothelial and 
subendothelial cells, platelets, leucocytes, coagulation factors and coagulation inhibitors 
(Curry & Pierce, 2007). 
 
1.5.1 Coagulation system 
 
The three major steps of coagulation process are the initiation, amplification and 
propagation phases. Vascular injury leads to intravascular exposure of tissue factor (TF). 
Tissue factor binds circulating factor VII to form TF-VII complexes. This initial step 
results in activation of factor X and IX on TF-bearing cells (initiation phase). Platelets 
are localized to the site of injury by adhesion to the subendothelial matrix mediated by 
interaction between collagen, von Willebrand factor (vWF) and GP 1b receptors on the 
surface of platelets. During initiation phase, activated factor X (FXa) generates small 
amount of thrombin, which is not high enough to produce a haemostatic sufficient fibrin 
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clot, but leads to an activation of platelets and further enzymatic coagulation factors 
(factor XI, VIII and V) (amplification phase). 
 
Activated platelets release thromboxane and their granular contents (serotonin, vwF, 
calcium and coagulation factors) which stimulate aggregation of platelets. Platelets also 
alter their surface by expressing negative charged phospholipids to facilitate calcium-
mediated coagulation factor binding. Activation of coagulation factors and subsequent 
thrombin generation takes place on the surface of activated platelets (propagation phase). 
Thrombin itself potentiates its generation by activation of factor XI, VIII, and V, which 
results in a thrombin burst, sufficient to cleave fibrinogen and activate factor XIII as 
well as thrombin activatable fibrinolysis inhibitor (TAFI). Soluble fibrin monomers 
polymerize and are cross-linked by FXIII. A mixture of fibrin and platelets form a stable 
clot which is anchored at the extracellular matrix due to the cross-linking of fibrin with 
adhesive protein (Gerlach et al., 2009). The steps in the coagulation cascade are 
simplified in Figure 1.3. 
 
Fibrin is then cross linked by FXIII to be stabilized further by incorporation of the 
fibrinolysis inhibitors alpha-2-antiplasmin and TAFI (thrombin activatable fibrinolysis 
inhibitor) and binding to several adhesive proteins of various cells (Muzbek et al., 2008). 
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Figure 1.3:  Summary of steps in coagulation cascade (Adapted from Contin 
Educational Anesthesiology Critical Care Pain article, 2007, Curry A & Pierce JM, 
2007). 
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1.5.2 Fibrinolytic System 
                                       
The fibrinolytic system is responsible for the degradation of the solid-phase fibrin 
network that constitutes the major protein component of thrombus to fibrin degradation 
product (FDP). As a consequence, the fibrinolytic system facilitates the dissolution of 
blood clots after repairing of a locally injured vessel wall and thus ensures an 
unobstructed circulation. The component of the system includes plasminogen and 
plasmin, several endogenous and exogenous plasminogen activators and their inhibitors.  
 
Fibrinolysis is initiated by either one of the serine protease urokinase-type plasminogen 
activator (u-PA) or tissue-type plasminogen activator (t-PA). The activity of the t-PA is 
dependent on the presence of the obligatory cofactor fibrin. Binding of t-PA to fibrin 
increases the affinity of t-PA for the zymogen plasminogen by two or three orders of 
magnitude, resulting in a significant acceleration of the conversion of the substrate into 
the active enzyme plasmin. Plasmin is rather a specific serine protease that recognizes 
and digests lysyl and arginyl-peptide bonds and converts insoluble, intact fibrin 
polymers into a distinct series of soluble degradation products. This fibrinolytic process 
is mainly controlled by two homologous proteins that exert a similar mechanism of 
action:  
(1) Plasminogen activator inhibitor type 1 (PAI-1), a 50 Kd glycoprotein that rapidly 
forms inactive, 1:1 equimolar complexes with t-PA (and with the non – fibrin specific    
u-PA). (2) The activity of plasmin is controlled by α2-antiplasmin, a glycoprotein that is 
present at high concentration in plasma (Geoffrey et al., 2005). The overall fibrinolytic 
activity is summarized in Figure 1.4. 
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                    Figure 1.4:  Schematic illustration of physiologic fibrinolysis 
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1.5.3 Natural inhibitors/ natural anticoagulant of coagulation system. 
 
The coagulation pathway is also regulated via inhibitory systems.  The inhibitory 
systems consists of  tissue factor pathway inhibitor (TFPI), antithrombin (AT), heparin 
cofactor II (HC II) activity and protein C activity. TFPI targets the initiation of 
coagulation, AT and HC II activity blocks thrombin generation and thrombin activity, 
and protein C inhibits the propagation of coagulation, as shown in Figure 1.5. 
 
Coagulation pathway
FX,FV
activated by cascade of intrinsic and extrinsic( FVII) pathways                 
FVa,                                                               
Phospholipids      +                                            
prothrombin +                       
Prothrombin
Fragment 1 and 2                      
thrombin                    Heparin Cofactor II
Fibrinogen                    
Fibrin monomer
F ibrin network
( clot)
 
Figure 1.5: Schematic diagram of regulation of coagulation. Formation of a clot is 
highly regulated by natural anticoagulant mechanisms that confine the haemostatic 
process to the site of injury in the vessel.  
 
The overall relationships between coagulation, fibrinolytic, platelet and endothelial cell 
components of the haemostatic system are described in Figure 1.6. 
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Figure 1.6: Interrelationships between the coagulation, fibrinolytic and endothelial cell 
components of the haemostatic system. Thrombin generated in the coagulation 
component influences events in other component: Antithrombin, PAI-1, PAP, plasmin-
antiplasmin complex (marker of plasmin generation); TAT; thrombin-antithrombin 
complex (marker of thrombin generation); TFPI; t-PA; uPA, urokinase type 
plasminogen activator. (Adapted from Hester et al., 1997) 
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1.6  Justification of the study 
 
Haemostatic markers contribute to the pathogenesis of obesity-related co morbidities 
such as cardiovascular disease and even modest weight loss reverses endothelial 
dysfunction and restores arterial homeostasis stress markers which potentially decrease 
the cardiovascular risk (Poobalan et al., 2007). However the levels of haemostatic 
markers need to be serially assessed to prove its reversibility to normal levels following 
the weight loss intervention.  
 
Even though there were many studies on weight loss program, majority of them were 
done in the western settings. Relatively very few studies were published in the Asian 
region, especially in Malaysia. To date, very few studies looked at the effects of weight 
loss program on both the fibrinolytic and pro-thrombotic markers of hemostatic system 
and none has assessed on extensive haemostatic markers for evaluation of the weight 
loss program. In this COMBINE program, participants were encouraged to set modest 
(reasonable) weight loss goals instead of striving for the ideal body weight for their 
height (Rohana et al., 1997, 1999 & 2007). This practice was based on the result from 
other studies (Foster et al., 1995) that have suggested losing 5% to 15% of body weight 
within 3 to 6 months is associated with substantial improvements in obesity-related 
conditions such as metabolic syndrome, cardiovascular disease and hypertension.  
 
This study was done to fill the research gap related to obesity and to explore the effect of 
weight loss on the hazard biomarkers, with special interest on haemostatic parameters. 
The effectiveness of a specific weight loss program therefore can be evaluated in this 
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intervention study prescribed 
 
in Obesity clinic, Universiti Sains Malaysia. This study 
investigates both physical and biochemical parameters of the subjects and their 
correlations with the levels of haemostatic markers.  Thus the findings will be useful in 
future to be used as predictive markers for evaluation of the weight loss program. It is 
hoped that this specific program will help obese subjects to reduce their body weight and 
decrease the cardiovascular risks and eventually lead to a healthier lifestyle. 
1.7   General objectives 
 
To study physical, biochemical parameters and levels of haemostatic prothrombotic 
markers predisposing to cardiovascular risks in obese subjects participating in the 
COMBINE weight loss program. 
  
1.8     Specific objectives 
 
1. To compare physical parameters; BMI, waist circumference and body fat composition 
at pre and post COMBINE weight loss program.  
 
2. To compare levels of haemostatic markers pre and post COMBINE weight loss 
program. 
 
3. To determine correlation between haemostatic parameters and physical- biochemical 
parameters among the subjects participating in COMBINE program. 
 
 
 
